Compare,PMID,Parameter,Sentece,Title,Type,URL,Units,Value,id,Drugbank_id,Name
,8748391,t1/2,"In addition, the t1/2 of the active moiety was prolonged (19 h in young subjects versus about 25 h in elderly and renal disease patients).","Influence of age, renal and liver impairment on the pharmacokinetics of risperidone in man. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8748391/),h,19,81649,DB00372,Thiethylperazine
,8748391,t1/2,"In addition, the t1/2 of the active moiety was prolonged (19 h in young subjects versus about 25 h in elderly and renal disease patients).","Influence of age, renal and liver impairment on the pharmacokinetics of risperidone in man. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8748391/),h,25,81650,DB00372,Thiethylperazine
,28092984,systemic clearance,"ViperaTAb®'s systemic clearance, distribution and elimination half-lives were 4.3-13.4 mL/h/kg, 1.2-3.2 h and 14.1-55.4 h, respectively.",Vipera ammodytes bites treated with antivenom ViperaTAb: a case series with pharmacokinetic evaluation. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28092984/),[ml] / [h·kg],4.3-13.4,210456,DB00372,Thiethylperazine
,28092984,distribution,"ViperaTAb®'s systemic clearance, distribution and elimination half-lives were 4.3-13.4 mL/h/kg, 1.2-3.2 h and 14.1-55.4 h, respectively.",Vipera ammodytes bites treated with antivenom ViperaTAb: a case series with pharmacokinetic evaluation. ,CL12-Q30,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28092984/),h,1.2-3.2,210457,DB00372,Thiethylperazine
,28092984,elimination half-lives,"ViperaTAb®'s systemic clearance, distribution and elimination half-lives were 4.3-13.4 mL/h/kg, 1.2-3.2 h and 14.1-55.4 h, respectively.",Vipera ammodytes bites treated with antivenom ViperaTAb: a case series with pharmacokinetic evaluation. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/28092984/),h,14.1-55.4,210458,DB00372,Thiethylperazine
